2022
DOI: 10.37047/jos.2022-90679
|View full text |Cite
|
Sign up to set email alerts
|

Predictive and Prognostic Value of ABO Blood Group in Patients Using Immune Checkpoint Inhibitor for Advanced Renal Cell Carcinoma

Abstract: We investigated the prognostic and predictive effects of the ABO blood group system on patients receiving immune checkpoint inhibitors for advanced renal cell carcinoma (RCC). Material and Methods: In this retrospective observational study, the data on the patients with known ABO blood group, who were administered nivolumab for mRCC, were reviewed. The tumor response rates and survival were analyzed based on the ABO blood group. Results: A total of 89 patients were included in the study. The median age of the … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 11 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?